%0 Journal Article
%A Brenner, Bluma G
%A Thomas, Rejean
%A Blanco, Jose Luis
%A Ibanescu, Ruxandra-Ilinca
%A Oliveira, Maureen
%A Mesplede, Thibault
%A Golubkov, Olga
%A Roger, Michel
%A Garcia, Federico
%A Martinez, Esteban
%A Wainberg, Mark A
%T Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
%D 2016
%U http://hdl.handle.net/10668/9956
%X Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine to dolutegravir monotherapy. The G118R mutation also arose in a treatment-experienced patient switched to dolutegravir monotherapy. The genetic basis for G118R selection and potential phenotypic outcome was ascertained. Genotypic analysis was performed on patients with virological failure ( We report on two patients who developed viral failure while on dolutegravir monotherapy. Both patients had been on a current or previous regimen containing integrase inhibitors. Virological failure ( Although resistance to dolutegravir is typically rare, genetic polymorphisms and monotherapy can facilitate the acquisition of G118R.
%K HIV Integrase Inhibitors
%K Heterocyclic Compounds, 3-Ring
%K Oxazines
%K Piperazines
%K Pyridones
%~